Alcinous Pharmaceuticals: Principles of bio-therapeutics design
Alcinous Pharmaceuticals: Principles of bio-therapeutics design
Join Nicholas (Nick) DaSilva, PhD, CEO of Alcinous Pharmaceuticals as he discusses his organizations innovative approach to bio-therapeutics design. Alcinous Pharmaceuticals strives to design and develop therapeutics for aggressive cancers. Founded in 2016 by three PhD students at the University of Rhode Island, this startup uses a novel drug discovery pipeline in tandem with their innovative team to develop new classes of therapeutics. Alcinous designs and develops new molecules that modulate the activity of well-established protein targets related to oncology and other pathologies. Their computational and synthetic approaches facilitate the identification and development of novel target ligands and new therapeutics.
Date and Time
Location
Hosts
Registration
- Date: 10 Dec 2020
- Time: 05:00 PM to 06:00 PM
- All times are (GMT-05:00) US/Eastern
-
Add Event to Calendar
- WEBINAR, Rhode Island
- United States
- Contact Event Hosts
-
Gary Dahrooge, IEEE Senior Member, Providence Section EMBS chair
- Starts 17 November 2020 12:00 AM
- Ends 10 December 2020 06:00 PM
- All times are (GMT-05:00) US/Eastern
- No Admission Charge
Speakers
Nicholas (Nick) DaSilva, PhD of https://www.alcinouspharmaceuticals.com
Principles of bio-therapeutics design
Nicholas (Nick) DaSilva, PhD, CEO, Alcinous Pharmaceuticals
Biography:
Dr. DaSilva is a passionate and entrepreneurial pharmaceutical scientist possessing extensive scientific knowledge gleaned from university-based research and the launch of an emerging pharmaceutical company. Also possesses invaluable technical experience in: pharmacology, molecular biology, medicinal chemistry, and oncology. A multi-award winning leader, consistently bestowed with greater responsibility due to a demonstrated commitment to excellence.